982: Madan RA, Heery CR, Gulley JL. Poxviral-based vaccine elicits immunologic
responses in prostate cancer patients. Oncoimmunology. 2014 Apr 29;3:e28611.
eCollection 2014. PubMed PMID: 25097802; PubMed Central PMCID: PMC4091323.


983: Madan RA, Gulley JL, Kantoff PW. Demystifying immunotherapy in prostate
cancer: understanding current and future treatment strategies. Cancer J. 2013
Jan-Feb;19(1):50-8. doi: 10.1097/PPO.0b013e31828160a9. PubMed PMID: 23337757;
PubMed Central PMCID: PMC3556901.


984: Madan RA, Arlen PM. Recent advances revolutionize treatment of metastatic
prostate cancer. Future Oncol. 2013 Aug;9(8):1133-44. doi: 10.2217/fon.13.65.
Review. PubMed PMID: 23902245.


985: Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM,
Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in
metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012
Feb 10. PubMed PMID: 22326924.


986: Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of
TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012 Jun;39(3):296-304.
doi: 10.1053/j.seminoncol.2012.02.010. Review. PubMed PMID: 22595052; PubMed
Central PMCID: PMC3398615.


987: Madan RA, Schwaab T, Gulley JL. Strategies for optimizing the clinical
impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer. J
Natl Compr Canc Netw. 2012 Dec 1;10(12):1505-12. PubMed PMID: 23221788.


988: Madan RA, Gulley JL. Therapeutic cancer vaccine fulfills the promise of
immunotherapy in prostate cancer. Immunotherapy. 2011 Jan;3(1):27-31. doi:
10.2217/imt.10.77. PubMed PMID: 21174555; PubMed Central PMCID: PMC3474245.


989: Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in
metastatic castration-resistant prostate cancer: principles in clinical trial
design. Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi:
10.1517/14712590903321421. PubMed PMID: 19857185.


990: Madan RA, Gulley JL. The current and emerging role of immunotherapy in
prostate cancer. Clin Genitourin Cancer. 2010 Dec 1;8(1):10-6. doi:
10.3816/CGC.2010.n.002. Review. PubMed PMID: 21208850; PubMed Central PMCID:
PMC3447981.


991: Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a
vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig
Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Review. PubMed
PMID: 19548854; PubMed Central PMCID: PMC3449276.